CIDP — Advanced Treatment Approaches

Comprehensive management of chronic inflammatory demyelinating polyneuropathy with first-line therapies (intravenous immunoglobulin, corticosteroids, plasma exchange), maintenance subcutaneous immunoglobulin, and emerging targeted therapies (rituximab, FcRn inhibitors, complement-blocking agents) for refractory disease.

Written by: Saygı Hospital Health Guide Editorial Board

Last updated: June 10, 2026

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Nöroloji department. Book Appointment →

What is CIDP — Advanced Treatment Approaches?

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated disorder of peripheral nerves characterized by chronic, progressive, or relapsing motor and sensory symptoms over more than 8 weeks, with characteristic electrodiagnostic features of demyelination and response to immunomodulatory therapy.

Advanced disease management requires accurate phenotyping into typical CIDP, distal acquired demyelinating symmetric (DADS), Lewis-Sumner syndrome (multifocal acquired demyelinating sensory and motor), pure motor or sensory CIDP, and identification of nodopathies with anti-neurofascin or anti-contactin antibodies that respond differently to standard therapies.

Treatment is individualized to disease activity, severity, and patient-specific factors, integrating intravenous or subcutaneous immunoglobulin, corticosteroids, plasma exchange, immunosuppressants (azathioprine, mycophenolate, methotrexate), and emerging biologics such as rituximab, efgartigimod, and complement inhibitors for autoantibody-positive variants.

Symptoms

Symmetric proximal and distal limb weakness developing over weeks to months

Sensory loss with numbness, paresthesia, and gait ataxia

Areflexia or hyporeflexia, particularly of ankle and knee jerks

Possible cranial nerve involvement: facial weakness, dysphagia, ophthalmoparesis (more common in atypical variants)

Tremor and ataxia in distal acquired demyelinating symmetric (DADS) variant with anti-MAG antibodies

Variable response to standard therapies in autoantibody-mediated nodopathies (anti-neurofascin 155, anti-contactin 1, anti-CASPR1)

Risk Factors

Diabetes mellitus, which increases risk and modifies treatment response

Underlying monoclonal gammopathy of uncertain significance, especially with IgM

Coexistent autoimmune diseases such as systemic lupus erythematosus, inflammatory bowel disease

Recent vaccination or infection acting as triggers in some patients

Anti-neurofascin 155, anti-contactin 1, anti-CASPR1, or anti-pan-neurofascin autoantibodies indicating CIDP variants with poor response to IVIG

Older age and male sex, with peak incidence in middle-aged and older adults

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

Patient with progressive limb weakness over weeks to months — neurology referral with electrodiagnostic studies and CIDP workup
Established CIDP patient with treatment failure or worsening despite first-line therapy — referral to peripheral nerve specialist for advanced workup including autoantibody testing
Patient developing severe respiratory weakness, bulbar symptoms, or rapid deterioration — emergency hospitalization with possible mechanical ventilation
Patient on long-term immunoglobulin or steroid therapy with treatment-related complications — multidisciplinary review
Pregnancy planning in CIDP patient — joint care with obstetrics, neurology, and clinical pharmacology

Treatment Methods

First-line therapy with intravenous immunoglobulin (IVIG) 2 g/kg loading then maintenance every 2–6 weeks, oral corticosteroids (prednisone 1 mg/kg/day with taper), or plasma exchange in severe cases

Maintenance subcutaneous immunoglobulin (SCIg) for stable patients to provide steady serum levels and avoid wear-off effects

Steroid-sparing immunosuppressants: azathioprine, mycophenolate mofetil, methotrexate, or cyclosporine for long-term control

Rituximab for refractory CIDP, particularly with anti-neurofascin or anti-contactin antibodies; efgartigimod (anti-FcRn) and complement inhibitors emerging for selected variants

Multidisciplinary supportive care including physical and occupational therapy, orthotics, neuropathic pain management, and assessment of treatment-related side effects (osteoporosis, infection, thrombosis)

Which Department to Visit?

You can visit our Nöroloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Nöroloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book Appointment Contact Us

CIDP — Advanced Treatment Approaches

What is CIDP — Advanced Treatment Approaches?

Symptoms

Risk Factors

When to See a Doctor?

Treatment Methods

Which Department to Visit?

Let us help you

Related Health Topics

Headache and Migraine

Low Back Pain

Neck Pain and Cervical Disc Herniation

Epilepsy

Parkinson Disease

Alzheimer's Disease and Dementia

Multiple Sclerosis (MS)

Stroke